计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E129897-1g |
1g |
现货 ![]() |
| |
| E129897-5g |
5g |
现货 ![]() |
| |
| E129897-25g |
25g |
现货 ![]() |
|
| 别名 | 依帕司他 | 益帕瑞司特 |
|---|---|
| 英文别名 | HMS3887A17 | {5-[(E)-2-Methyl-3-phenyl-prop-2-en-(Z)-ylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid | GTPL11371 | ONO 2 | s2035 | Epalrestat- Bio-X | CCG-267693 | MFCD00865484 | CHNUOJQWGUIOLD-NFZZJPOKSA-N | HMS2747M09 | AS-13345 | EPALRESTAT [MI] |
| 规格或纯度 | Moligand™, ≥97% |
| 英文名称 | Epalrestat |
| 生化机理 | 强大的醛糖还原酶抑制剂(IC 50 = 72 nM)。通过转录调控增加雪旺细胞中细胞内谷胱甘肽的水平。在体内显示出抗糖尿病和神经保护作用。口服具有活性 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 醛糖还原酶抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 纯度 | ≥97% |
| ALogP | 3.8 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504760585 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid |
| INCHI | 1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8- |
| InChi Key | CHNUOJQWGUIOLD-NFZZJPOKSA-N |
| Smiles | CC(=CC1=CC=CC=C1)C=C2C(=O)N(C(=S)S2)CC(=O)O |
| Isomeric SMILES | C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O |
| 分子量 | 319.4 |
| Reaxy-Rn | 15484334 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=15484334&ln= |
| 溶解性 | DMSO 2 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 熔点 | 224 °C |
| 分子量 | 319.400 g/mol |
| XLogP3 | 3.800 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 319.034 Da |
| 单同位素质量Monoisotopic Mass | 319.034 Da |
| 拓扑极表面积Topological Polar Surface Area | 115.000 Ų |
| 重原子数Heavy Atom Count | 21 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 519.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 2 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 2 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N et al.. (2006) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.. Diabetes Care, 29 (7): (1538-44). [PMID:16801576] |
| 2. Ramirez MA, Borja NL. (2008) Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.. Pharmacotherapy, 28 (5): (646-55). [PMID:18447661] |
| 3. Ji J, Xu MX, Qian TY, Zhu SZ, Jiang F, Liu ZX, Xu WS, Zhou J, Xiao MB. (2020) The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer.. Mol Biol Rep, 47 (8): (6091-6103). [PMID:32761301] |
| 4. Geng N, Jin Y, Li Y, Zhu S, Bai H. (2020) AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma.. Int J Med Sci, 17 (9): (1246-1256). [PMID:32547320] |
| 5. Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y, Terashima H, Morimura T, Tsuboshima M. (1983) Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.. Diabetologia, 24 (4): (290-2). [PMID:6407887] |
| 6. Kikkawa R, Hatanaka I, Yasuda H, Kobayashi N, Shigeta Y. (1984) Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.. Metabolism, 33 (3): (212-4). [PMID:6420645] |
| 7. Takahashi M, Fujii J, Miyoshi E, Hoshi A, Taniguchi N. (1995) Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes.. Int J Cancer, 62 (6): (749-54). [PMID:7558425] |
| 8. Yamaori S, Araki N, Shionoiri M, Ikehata K, Kamijo S, Ohmori S, Watanabe K. (2018) A Specific Probe Substrate for Evaluation of CYP4A11 Activity in Human Tissue Microsomes and a Highly Selective CYP4A11 Inhibitor: Luciferin-4A and Epalrestat.. J Pharmacol Exp Ther, 366 (3): (446-457). [PMID:29976573] |